Information for Domestic U.S. customers
I acknowledge that Epigenomics currently does not sell or make
available the Septin9 test Epi proColon in the U.S.
While a Septin9 biomarker colorectal cancer diagnostic test is available from Epigenomics
in Europe, Epigenomics currently does not sell or make available any such test in either
Canada or the USA. Epigenomics is in the process of seeking regulatory approval/
clearance for these markets, so please check back at our site for the latest developments.
Epigenomics has licensed its Septin9 colorectal cancer biomarker and methylation
technology to a number of clinical laboratories, more particularly, Warnex in Canada and
Quest Laboratory and ARUP in the USA.
Epigenomics understands that each of these clinical laboratories has chosen, independent
of any participation by Epigenomics, to develop, validate, and market a diagnostic
testing service using the Septin9 biomarker and associated technology. Such services
are only available by request from a physician.
Because Epigenomics was not involved in the development of and in no way supports
these Septin9 laboratory testing services, it cannot provide a guarantee or validation
with regard to the analytical and clinical performance characteristics of such independent
Septin9 testing services.
CONTINUE
